Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122939 | 0.90 | GRM5 (0.43) | GRM5MAP3K14 | |
| SCHEMBL5130025 | 0.89 | GRM5 (0.44) | GRM5MAP3K14PTGES | |
| SCHEMBL5122918 | 0.87 | GRM5 (0.54) | GRM5 | |
| SCHEMBL5115831 | 0.87 | GRM5 (0.43) | GRM5CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5124137 | 0.86 | GRM5 (0.50) | GRM5PTGES | |
| SCHEMBL5125859 | 0.84 | GRM5 (0.47) | GRM5PTGES | |
| SCHEMBL5124317 | 0.83 | GRM5 (0.45) | GRM5MAP3K14PTGES | |
| SCHEMBL5115129 | 0.81 | HTR2A (0.42) | GRM5MAP3K14PTGES | |
| SCHEMBL5129624 | 0.80 | GRM5 (0.45) | GRM5MAP3K14PTGES | |
| SCHEMBL5122183 | 0.80 | GRM5 (0.43) | GRM5MAP3K14PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885CHRNB2 337/4885CHRNA4 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.